Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanxi Jinbo Bio pharmaceutical CoBJSE:920982 78 Pretax Margin % is 44.48% as of Mar. 2026, which is 12% above its 10-year median of 39.58. GuruFocus rates BJSE:920982 with a GF Score™ of 78/100 and a GF Value™ of ¥282.38 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 945 Biotechnology companies, Shanxi Jinbo Bio pharmaceutical Co ranks better than 93.86% on this metric.
The historical rank and industry rank for Shanxi Jinbo Bio pharmaceutical Co's Pretax Margin % or its related term are showing as below:
BJSE:920982'
s Pretax Margin % Range Over the Past 10 Years
Min: 22.08 Med: 39.58 Max: 59.43
Current: 45.51
BJSE:920982's Pretax Margin % is ranked better than 93.86% of 945
companies
in the Biotechnology industry
Industry Median: -90.63
vs BJSE:920982: 45.51
Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Shanxi Jinbo Bio pharmaceutical Co Pretax Margin % Related Terms
Shanxi Jinbo Bio pharmaceutical Co Pretax Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Jinbo Bio pharmaceutical Co Pretax Margin % Chart
BJSE:920982 vs VRTX, REGN, RVMD: Pretax Margin % Comparison
For the Biotechnology subindustry, Shanxi Jinbo Bio pharmaceutical Co's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanxi Jinbo Bio pharmaceutical Co Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanxi Jinbo Bio pharmaceutical Co's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Shanxi Jinbo Bio pharmaceutical Co's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) has a Pretax Margin % of 44.48% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shanxi Jinbo Bio pharmaceutical Co and its competitors. This is 12% above median its historical median of 39.58. Over the past decade, Shanxi Jinbo Bio pharmaceutical Co's Pretax Margin % has ranged from 22.08 to 59.43. According to the industry distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #58 out of 945 companies in the Biotechnology industry, placing it in the top 6.1%.
Is Shanxi Jinbo Bio pharmaceutical Co's Pretax Margin % too high?
Shanxi Jinbo Bio pharmaceutical Co's current Pretax Margin % of 44.48% is 12% above median its 10-year median of 39.58. Over the past 10 years, this metric has ranged from a low of 22.08 to a high of 59.43. Based on the distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #58 out of 945 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Shanxi Jinbo Bio pharmaceutical Co has a GF Score™ of 78/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Shanxi Jinbo Bio pharmaceutical Co's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanxi Jinbo Bio pharmaceutical Co ranks #58 out of 945 companies for Pretax Margin %. This places Shanxi Jinbo Bio pharmaceutical Co in the top 6% of its industry — outperforming the majority of peers. Historically, Shanxi Jinbo Bio pharmaceutical Co's own Pretax Margin % has ranged from 22.08 to 59.43 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Shanxi Jinbo Bio pharmaceutical Co and its competitors. Shanxi Jinbo Bio pharmaceutical Co's current Pretax Margin % is 44.48%, which is 12% above median its own 10-year median of 39.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanxi Jinbo Bio pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥282.38, compared to a current price of ¥129.49 — trading 54.1% below its estimated fair value. The current Pretax Margin % is 44.48%, which is 12% above median its 10-year median of 39.58. Shanxi Jinbo Bio pharmaceutical Co's overall GF Score™ is 78/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982), the current Pretax Margin % is 44.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanxi Jinbo Bio pharmaceutical Co (BJSE:920982) Overvalued in 2026?
Based on GuruFocus' analysis, Shanxi Jinbo Bio pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥129.49 is trading 54.1% below its estimated GF Value™ of ¥282.38.
GuruFocus considers Shanxi Jinbo Bio pharmaceutical Co to be Significantly Undervalued.
Key valuation signals for BJSE:920982:
Pretax Margin %: 44.48% (12% above median its 10-year median of 39.58)
GF Value™: ¥282.38 vs. price of ¥129.49 (54.1% below fair value)
No single metric tells the full story. See the BJSE:920982 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanxi Jinbo Bio pharmaceutical Co Ltd is engaged in research & development, production and sales of various medical devices and functional skin care products with recombinant collagen products and anti-HPV biological protein products as the core.
78GF Score
Get the complete analysis for BJSE:920982
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BJSE:920982 has been successfully added to your 
